



고려대학교의료원
KOREA UNIVERSITY MEDICINE

In Patients with VT Storm: **RF Ablation First!**

VT Symposium 2019

Nov 2, 2019

Jaemin Shim, MD, PhD


Arrhythmia Center,

Korea University Anam Hospital, Seoul, Korea

ENABLING
FUTURE MEDICINE



Diagnostic Evaluation




Underlying Substrate

- **Structural heart disease**
 - Ischemic heart disease
 - Non-ischemic cardiomyopathy
 - Others (VHD, myocarditis, sarcoidosis, etc.)
 - **Abnormal electrical substrate**
 - Brugada syndrome
 - Long QT syndrome
 - Early repolarization syndrome
 - Idiopathic VF
 - CPVT
-




Type of Arrhythmia


- **Monomorphic VT**




- **Polymorphic VT**



- **VF**



Type of Arrhythmia




■ Monomorphic VT ■ VF ■ Polymorphic VT

Expert Rev. Cardiovasc. Ther. 2011;9:1051–58



Clinical Triggers

- **Decompensated heart failure (m/c)**
- **Acute coronary ischemia**
- **Electrolyte abnormalities**
- **Proarrhythmic drugs**



Overview of Management

- Intensive care unit admission
 - Device reprogramming
 - Correct underlying problems (ischemia, electrolyte disturbances, pro-arrhythmic drugs)
 - Beta-blockade
 - Antiarrhythmic therapy
 - Sedation, intubation/deep sedation
 - Mechanical hemodynamic support (IABP)
 - **Neuraxial modulation** (thoracic epidural anesthesia, cardiac sympathetic denervation)
 - **Catheter ablation (any time it is feasible)**
-

2014 EHRA/HRS/APQRS Expert Consensus on Ventricular Arrhythmias



Four Clinical Scenarios

1. Monomorphic VT in structurally normal heart


2. Polymorphic VT/VF in structurally normal heart

3. Monomorphic VT in structural heart disease



4. Polymorphic VT/VF in structural heart disease




● M/65, Palpitation with dyspnea, EF 57.5%, minimal CAD






● Amiodarone infusion and repeated CV




● Refractory to amiodarone and repeated CV




● Catheter ablation



● Termination during ablation




● After ablation



Catheter Ablation in Electrical Storm

- 267 consecutive patients with NIDCM (n=71) and ICM (n=196)
- Elimination of ES in 95% of cases
- Achievement of complete VT control at long-term follow-up in most patients.




Muser D et al. J Am Coll Cardiol EP 2017;3:767–78



Catheter Ablation in Electrical Storm

- 267 consecutive patients with NIDCM (n=71) and ICM (n=196)
- Elimination of ES in 95% of cases
- Achievement of complete VT control at long-term follow-up in most patients.




Muser D et al. *J Am Coll Cardiol EP* 2017;3:767–78



Catheter Ablation in Electrical Storm


- 267 consecutive patients with NIDCM (n=71) and ICM (n=196)
- Elimination of ES in 95% of cases
- Achievement of complete VT control at long-term follow-up in most patients.



Muser D et al. *J Am Coll Cardiol EP* 2017;3:767–78



Catheter Ablation in Electrical Storm




Muser D et al. J Am Coll Cardiol EP 2017;3:767–78




Catheter Ablation in Electrical Storm

- 1940 patients from 12 centers undergoing VT ablation were compared between patients with and without ES.
- 677 patients with ES (34.9%)

Kaplan-Meier curves of survival in patients with and without ES



Number	No ES	1262	1044	985	963
at risk	ES	677	517	471	421




Number	No inducible VTs	394	331	311	281
at risk	Non-clinical VT inducible	139	101	86	73
	Clinical VT inducible	42	23	18	15
	Not tested	39	24	21	20

Vergara P et al. Heart Rhythm 2018;15:48–55



SGB in Electrical Storm

- 30 consecutive patients (age, 58 ± 14 years; 73.3% men) who had undergone SGB for ES between 2013 and 2018 at Mayo Clinic
- VT storm 12 (40%), VT+VF storm 15 (50%), VF storm 3 (10%)
- **AMI 9 (30%), postop 10 (33%)**



Tian Y et al. *Circ Arrhythm Electrophysiol.* 2019;12:e007118



Evidence of SGB in Electrical Storm

- Only case series without control group (max N=30)
- Many confounding factors due to coexistent therapy
- No tool to evaluate completeness of SGB
- Operator dependent efficacy and safety

Validation in a prospective randomized trial is needed.



KUMC Experiences

- From May 2018 to July 2019, N=6

	Age	Sex	Underlying disease	Type of VA	Short term outcome	Catheter Ablation	Long term outcome
Patient 1	72	F	HCMP	MMVT	Recur next day	Yes 2 days later	Deceased 1m later
Patient 2	62	F	NICMP	MMVT	Recur 4 days later	Yes 6 days later	VT free for 15m
Patient 3	23	M	JWS	VF	Recur 16 days later	Yes 55 days later	VF recur 4m later
Patient 4	59	M	NICMP	MMVT	Recur next day	FU lost	FU lost
Patient 5	75	F	HFrEF, s/p AVR	MMVT	No recur	Yes , 6 days before SGB	VT free for 4m
Patient 6	89	F	NICMP	TdP	No recur	No (PM 2m later)	VT free for 3m



RFCA vs. SGB in Electrical Storm

	RFCA	SGB
Clinical setting	Chronic CMP	AMI, postop
Type of arrhythmia	Monomorphic VT	Polymorphic VT, VF
Recommendation	Class I (LOE B-R)* Class IIa (LOE B-NR)**	Class IIb (LOE C-LD)#

*: for ischemic CMP

** : for non-ischemic CMP

#: for cardiac sympathetic denervation, no recommendation for SGB yet



In Patients with VT Storm

*Whenever it is feasible,
Catheter ablation should be first!*





고려대학교의료원

KOREA UNIVERSITY MEDICINE

